Clinical Trial Update: Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating icotinib at different doses as second-line treatment for patients with non-small cell lung cancer and wild-type EGFR.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN